Michael McDonald, MD

Overview

Michael W. McDonald, MD is a board-certified urologist with over 20 years of experience, focusing on minimally- invasive techniques, including robotics. Dr. McDonald uses the state-of-the-art technology of the daVinci® Surgical System to treat patients with kidney, prostate and other urologic disorders. Additionally, Dr. McDonald is an Assistant Professor of Urology at the University of Central Florida College of Medicine and performs surgery at AdventHealth Celebration, where his new practice is located.

Articles

The Effect of Digital Three-Dimensional Reality Models on Patient Counseling for Renal Masses

JSLS-JOURNAL OF THE SOCIETY OF LAPAROENDOSCOPIC SURGEONS

2023

Sparing the Prod: Providing an Alternative to Endomyocardial Biopsies With Noninvasive Surveillance After Heart Transplantation During COVID-19.

CJC open

2022

Is it Time to Say Goodbye to Culture and Sensitivity? The Case for Culture-independent Urology

UROLOGY

2020

Metagenomics in diagnosis and improved targeted treatment of UTI

WORLD JOURNAL OF UROLOGY

2020

Neurohormone levels remain elevated in continuous flow left ventricular assist device recipients

JOURNAL OF CARDIAC SURGERY

2018

A Head-to-Head Comparative Phase II Study of Standard Urine Culture and Sensitivity Versus DNA Next-generation Sequencing Testing for Urinary Tract Infections.

Reviews in urology

2017

A Matched Cohort Study of Patients With End-Stage Heart Failure from Anthracycline-Induced Cardiomyopathy Requiring Advanced Cardiac Support

AMERICAN JOURNAL OF CARDIOLOGY

2016

Longitudinal Assessment of Inflammation in Recipients of Continuous-Flow Left Ventricular Assist Devices

CANADIAN JOURNAL OF CARDIOLOGY

2015

Markers of Inflammation in Recipients of Continuous-Flow Left Ventricular Assist Devices

ASAIO JOURNAL

2014

Cardiac resynchronization therapy in mildly symptomatic heart failure: the earlier the better

EXPERT REVIEW OF CARDIOVASCULAR THERAPY

2011

Associated Clinical Trials

NCT05820087

HOPE4KIDNEY: The HistoSonics Edison System for treatment of primary solid renal tumors using histotripsy (#HOPE4KIDNEY US)

This study is currently enrolling.

Study Purpose: The purpose of this trial is to evaluate the effectiveness and safety of the HistoSonics Edison System for the destruction of kidney tissue by treating primary solid renal tumors. To be enrolled in this study, y ...

Michael McDonald , MD

Overview

Articles

The Effect of Digital Three-Dimensional Reality Models on Patient Counseling for Renal Masses

Sparing the Prod: Providing an Alternative to Endomyocardial Biopsies With Noninvasive Surveillance After Heart Transplantation During COVID-19.

Is it Time to Say Goodbye to Culture and Sensitivity? The Case for Culture-independent Urology

Metagenomics in diagnosis and improved targeted treatment of UTI

Neurohormone levels remain elevated in continuous flow left ventricular assist device recipients

A Head-to-Head Comparative Phase II Study of Standard Urine Culture and Sensitivity Versus DNA Next-generation Sequencing Testing for Urinary Tract Infections.

A Matched Cohort Study of Patients With End-Stage Heart Failure from Anthracycline-Induced Cardiomyopathy Requiring Advanced Cardiac Support

Longitudinal Assessment of Inflammation in Recipients of Continuous-Flow Left Ventricular Assist Devices

Markers of Inflammation in Recipients of Continuous-Flow Left Ventricular Assist Devices

Cardiac resynchronization therapy in mildly symptomatic heart failure: the earlier the better

Education & Training

Education

Residency

Fellowship

Specialty

Board Certifications

Associated Clinical Trials

HOPE4KIDNEY: The HistoSonics Edison System for treatment of primary solid renal tumors using histotripsy (#HOPE4KIDNEY US)

Explore

Institutes